8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its next generation targeted radiopharmaceutical technology platformFour additional new assets being evaluated for IND development, to be guided by first-in-human imagesMaking progress on plans to expand manufacturing capabilities by improving efficiencies of existing facilities and building out recently acquired sites, while evaluating additional capacity expansion opportunitiesPreliminary unaudited cash, cash equivalents and short-term investments of $227.8M as of December 31, 2024 expected to be suffici

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT. Management will also participate and present at the Biotech Showcase conference alongside the J.P. Morgan Healthcare Conference in San Francisco. 43rd Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednesday, January 15, 2025Time: 3:45 p.m. - 4

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. 36th Annual Piper Healthcare ConferenceDate: December 3, 2024Location: New York, NYFormat: Fireside ChatTime: 10:00-10:25 AM ET 7th Annual Evercore HealthCONxDate: December 5, 2024Location: Coral Gables, FLFormat: Fireside ChatTime: 10:50-11:10 AM ET Webcast events can be acce

[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction of tumor volume, one of whom had a confirmed response as defined by RECIST v1.1. Signal of anti-tumor activity was generally more pronounced in patients with lower body weightPerspective is continuing all required activities to pursue dose escalation according to Safety Monitoring Committee recommendations; recruitment is ongoing at 5.0 mCi SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Symposium in NovemberShipping of investigational product started in October from a second manufacturing facility in Somerset, New Jersey; additional facility expansion activities ongoingOn track to adva

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment ap

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Truist Securities BioPharma SymposiumDate: November 7, 2024Location: Lotte New York Palace - New York, NYFormat: 1x1 meetings only UBS Global Healthcare ConferenceDate: November 13, 2024Location: Rancho Palos Verdes, CAFormat: Fireside ChatTime: 2:45 p.m. – 3:20 p.m. PT / 5:45 p

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024. "The preclinical studies and first-in-human imaging data presented with [212Pb]Pb-PSV359, our novel cyclic peptide targeting fibroblast activation protein-alpha, are very encouraging and validate the potential of this radiopharmaceutica

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

3 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4/A - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4/A - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark

Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

UBS initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $20.00

Wedbush initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $25.00

Truist initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $21.00

BofA Securities initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $24.00

Cantor Fitzgerald initiated coverage of Perspective Therapeutics with a rating of Overweight

SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

SC 13D/A - Perspective Therapeutics, Inc. (0000728387) (Subject)